Article Text

other Versions

Evaluation of topical cyclosporine A 0.05% for prevention of rejection in high-risk corneal grafts
  1. Mustafa Ünal (mustafaunalmd{at},
  2. Ýclal Yücel (drmustafaun{at}
  1. Akdeniz University Medical Faculty, Turkey
  2. Akdeniz University Medical Faculty, Turkey


    Purpose: To evaluate the efficacy of combined treatment with commercially available 0.05% topical cyclosporine (CsA) and topical corticosteroid compared to treatment with topical corticosteroids only after high risk keratoplasty.

    Patients and Methods: A total of 47 high-risk keratoplasties were randomly divided into two groups based on the postoperative immunosuppression. Twenty-five eyes (Group 1) were treated with 0.05% CsA and dexamethasone 0.1%, and 22 eyes (Group 2) were treated with dexamethasone only. The clinical outcome of penetrating keratoplasty (PK) was evaluated by the rate of rejection-free graft survival and graft survival evaluation by the Kaplan-Meier log-rank test.

    Results: The avarage length of follow-up was not 20.2±7.1 months in group1 and 18.5±6.6 months in group 2 (p=0.421). Rejection-free graft survival rates were 60.8% in group 1, and 54.5% in group 2 (Kaplan-Meier log-rank test, p=0.474). In group 1, the graft survival rate was 73.9%; in group 2, the graft survival rate was 68.1%. The difference in the graft survival rates between the groups was also not statistically significant (Kaplan-Meier log-rank test, p=0.518).

    Conclusion: In high risk corneal grafts, the efficacy of 0.05 percent commercially available topical cyclosporine combined with dexamethasone topically was not better than that of dexamethasone alone in preventing rejection.

    Statistics from

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    • At a glance
      Harminder S Dua Arun D Singh